CSBR.NASDAQChampions Oncology, INC

Form 4: Director Joel Ackerman Acquires CSBR Stock Options

Sentiment:

Insider Transaction Report

📋All filings for Champions Oncology, INC
🔒Login to Follow

Champions Oncology Director Joel Ackerman acquired 21,216 options to purchase common stock at an exercise price of $6.80 per share.

Better than expectedA director's acquisition of stock options is generally viewed as a positive signal, indicating management's confidence in the company's future prospects and aligning their financial interests with shareholders.

Summary

  • Joel Ackerman, a Director of Champions Oncology, Inc. (CSBR), acquired 21,216 options to purchase common stock.
  • The options have an exercise price of $6.80 per share.
  • The options vest over a twelve-month period, with vesting occurring on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.
  • The expiration date for these options is November 5, 2035.
  • Following this transaction, Mr. Ackerman beneficially owns 21,216 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is a positive indicator of insider confidence, aligning management's interests with shareholders, though it's a routine compensation event.

Positives

  • The acquisition of stock options by a director signals confidence in the company's future performance and aligns management's interests with those of shareholders.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting and expiration dates of the options.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

  • Shareholders may perceive the director's acquisition of options as a positive sign of confidence in the company's future, potentially influencing investor sentiment.

Next Steps

  • The options will vest in four tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.

Key Dates

DateDescription
11/05/2025Date of earliest transaction (acquisition of derivative securities).
11/05/2025First vesting date for the acquired options.
11/07/2025Date the Form 4 was signed and filed.
02/05/2026Second vesting date for the acquired options.
05/05/2026Third vesting date for the acquired options.
08/05/2026Fourth and final vesting date for the acquired options.
11/05/2035Expiration date of the acquired options.

Recommendation

hold

While a director acquiring stock options is a positive signal of insider confidence, a single Form 4 filing typically does not provide enough comprehensive information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position, suggesting continued monitoring of the company's performance and broader market conditions.

Keywords

Champions Oncology, CSBR, stock options, insider transaction, Form 4, director compensation, equity grant

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.